(Date:7/25/2008)... Though the number of jobs created ...l companies reported a different kind of slowdown:...us months. , Seattle, WA ... created in the medical field slowed in June overa...kind of slowdown that will be music to the ears of...
(Date:7/25/2008)... - 180-Days of Marketing Exclusivity Begins -...-- Watson,Pharmaceuticals, Inc. (NYSE: WPI ), a l... today that its subsidiary has commenced commercia...les USP product in the 40mg,strength from its Davi...with the launch, Watson has 180 days of marketing ...
(Date:7/25/2008)...BURG, Ill., July 25 /PRNewswire/ -- Sagent Pharmac...eutical company, today announced that it,has launc...iarrhythmic,indicated for the treatment and prophy...tion and hemodynamically unstable ventricular,tach...r heart beat.,Sagent,s amiodarone HCl injection wi...
(Date:7/25/2008)...AD, Calif., July 25 /PRNewswire/ -- AutoGenomics, ...ion statement on Form S-1 with the,Securities and ...al public,offering of shares of its common stock. ..., all of which are expected to be offered by,AutoG...g, have not yet been,determined., J.P. Morgan Sec...
Breaking Medicine News(10 mins):Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 2Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 3Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 3Health News:AutoGenomics, Inc. Files Registration Statement for Initial Public Offering 2(Date:7/24/2008)...y 24 /- Ortho-McNeil Neurologics, a,d...nc., announced today,that the U.S. Food and Drug A...ity for TOPAMAX(R) (topiramate), based on studies ...FDA to investigate the use of TOPAMAX,in pediatric...eizures., In addition to granting pediatric exclu...
(Date:7/24/2008)..., July 24 /- Alexza,Pharmac...at it has initiated,its second Phase 3 clinical tr...an inhalation product candidate being developed fo...h schizophrenia or bipolar disorder.,Alexza believ...cokinetic,(PK) properties resulting from inhaled l...
(Date:7/24/2008)...PRNewswire-USNewswire/ -- Headlines claiming "soy,...story. The small scale,preliminary study that Dr....ction, is based on recollected intake of soyfoods ...is study is confounded by many,issues, thus I feel...,caution," warned Dr. Tammy Hedlund, a researcher ...
(Date:7/24/2008)...eter designed to take body temperature, for home,a...e-FirstCall/ --- Kidz-Med, Inc.,(subsidiary of Ame...,United States distributor of the Thermofocus(R) ...unce the results of a clinical study,conducted by ...Milan, in,Milan, Italy, which proves that the Ther...
Breaking Medicine Technology:FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months 2FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months 3Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 2Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 3Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 4Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 5Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 6Soyfoods Do Not Impact Sperm Count 2Pediatric Study Finds 21st Century Non-Contact Thermometer as Accurate as Conventional Thermometers 2The Stay Strong Foundation Launches National Healing Starts With US Campaign With Celebrity Guests Denzel Washington Ruby Dee MoNique Terry McMilla 14367 1The Stay Strong Foundation Launches National Healing Starts With US Campaign With Celebrity Guests Denzel Washington Ruby Dee MoNique Terry McMilla 14367 2The Stay Strong Foundation Launches National Healing Starts With US Campaign With Celebrity Guests Denzel Washington Ruby Dee MoNique Terry McMilla 14367 330 National Organizations Issue Call to Action for Congress to Fully Fund Falls Prevention Programming in CDC Budget 14364 130 National Organizations Issue Call to Action for Congress to Fully Fund Falls Prevention Programming in CDC Budget 14364 230 National Organizations Issue Call to Action for Congress to Fully Fund Falls Prevention Programming in CDC Budget 14364 3JCI online early table of contents 3A March 13 2008 14362 1JCI online early table of contents 3A March 13 2008 14362 2JCI online early table of contents 3A March 13 2008 14362 3JCI online early table of contents 3A March 13 2008 14362 4JCI online early table of contents 3A March 13 2008 14362 5JCI online early table of contents 3A March 13 2008 14362 6JCI online early table of contents 3A March 13 2008 14362 7Lung Cancer Alliance Commends Leadership of MA State Senate 14360 1Lung Cancer Alliance Commends Leadership of MA State Senate 14360 2...DGEWATER, N.J., July 05, 2007 /PRNewswire/ -- Resu...trolled, open-label, Phase,3 study showed that 77 ...ults taking PREZISTA(TM) (darunavir) 600 mg tablet...plus an optimized,background regimen (OBR) of anti...ad of <400 copies/mL at week 48, compared to 68,pe...
...rst prospective biomarker trial in non-small cell ...ire-FirstCall/ -- Response,Genetics, Inc. today an...ished in the July 1 issue of the Journal of Clinic...omarker,Excision-Repair Cross-Complementing 1 (ERC...ell lung cancer (NSCLC) predicts for,sensitivity t...
Other Medicine Technology:New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 2New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 4New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 5New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 6New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 7New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 8Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 2Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 3Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 4The Libert Coronary Stent System introduces a new generation of lesion access and conformability. With exceptional flexibility, a low crossing profile, and the leading delivery catheter, the performa
..., and microplatesthat is the area of research in w...increasing force. Ergonomics (reduced weight and e...nel Research model was developed. This high-perfor... precise, and rapid processing of long series for ...
The Finnpipette Digital Multichannel, with it's streamlined design, makes even lighter work of routine laboratory tasks. The multichannel offers all these advanced features: Soft-touch tip ejection,
...mics, and value!, Comfortable feel and less hand ...er control while pipetting with smooth, light plun...long, lever tip ejector , Completely autoclavable ... the need for recalibration , Easy-to-read precisi...
Medicine Products: